FDA rejects Probuphine; Mayday, Mayday, Mayday for Titan shares
This article was originally published in Scrip
Executive Summary
May Day was anything but a celebration for Titan Pharmaceuticals, which watched helplessly as its stock lost 80% of its value in morning trading after the FDA rejected the firm's new drug application for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate) – an action the company's executive chairman, Dr Marc Rubin, said came as a surprise.